Sector: Indices SP 600
Latest Quote @ Fri May 5 17:04:22 (15 min delayed)
Last Day's Data
Cyberonics, Inc., a neuromodulation company, engages in the design, development, and commercialization of medical devices for the treatment of epilepsy, depression, and other chronic treatment-resistant disorders using vagus nerve stimulation (VNS) therapy. The VNS Therapy System, an implantable generator, delivers preprogrammed intermittent mild electrical pulses to the vagus nerve in the patient's neck continuously. VNS Therapy is approved for use as an adjunctive therapy in reducing the frequency of seizures in patients with partial onset seizures that are refractory or resistant to antiepileptic drugs and as a long-term adjunctive treatment for patients 18 years of age or older with chronic or recurrent treatment-resistant depression in a major depressive episode that has not responded to at least 4 adequate antidepressant treatments. VNS Therapy is at various levels of investigational clinical study as a treatment for anxiety disorders, Alzheimer's disease, chronic headache/migraine, and bulimia. The company sells and markets its products through direct sales force and distributors in the United States, Canada, Mexico, Europe, Asia, South Africa, and Australia. Cyberonics was co-founded by Jacob Zabara in 1987 and is headquartered in Houston, Texas.